Page last updated: 2024-08-22

ornithylaspartate and Chronic Illness

ornithylaspartate has been researched along with Chronic Illness in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jiang, L; Jiang, Y; Mao, Q; Wang, J; Wang, X; Wang, Y; Xiang, DD; Yan, Z; Zhang, X1
Bernauer, E; Finsterer, J1
Bueverov, AO; Nadinskaia, MIu; Podymova, SD1
Koczorek, M1

Trials

1 trial(s) available for ornithylaspartate and Chronic Illness

ArticleYear
[The treatment of hepatic encephalopathy with Hepa-Mertz].
    Terapevticheskii arkhiv, 1995, Volume: 67, Issue:6

    Topics: Ammonia; Biomarkers; Chronic Disease; Dipeptides; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Psychomotor Performance; Time Factors

1995

Other Studies

3 other study(ies) available for ornithylaspartate and Chronic Illness

ArticleYear
[Effect of L-ornithine L-aspartate granules in treating chronic liver disease in patients with high-level serum gamma-glutamyltransferase].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2014, Volume: 22, Issue:7

    Topics: Chronic Disease; Dipeptides; gamma-Glutamyltransferase; Humans; Liver Diseases; Liver Function Tests

2014
Recovery from parkinson syndrome and prolonged visually evoked potentials in hepatic encephalopathy.
    Metabolic brain disease, 2005, Volume: 20, Issue:1

    Topics: Anti-Bacterial Agents; Antiparkinson Agents; Benzothiazoles; Brain; Chronic Disease; Dipeptides; Evoked Potentials, Visual; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Paromomycin; Pramipexole; Recovery of Function; Thiazoles; Treatment Outcome; Vision Disorders

2005
[Chronic liver diseases. The nihilism has gone].
    MMW Fortschritte der Medizin, 2001, Dec-13, Volume: 143, Issue:51-52

    Topics: Amantadine; Antioxidants; Antiviral Agents; Chronic Disease; Dipeptides; Drug Therapy, Combination; Flumazenil; GABA Modulators; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Diseases; Pentoxifylline; Phosphodiesterase Inhibitors; Prospective Studies; Protective Agents; Ribavirin; Silymarin

2001